RhumbLine Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $381K | Buy |
111,412
+1,216
| +1% | +$4.04K | ﹤0.01% | 2927 |
|
|
2026
Q1 | $394K | Sell |
110,196
-3,224
| -3% | -$12.8K | ﹤0.01% | 2752 |
|
|
2025
Q4 | $398K | Sell |
113,420
-7,351
| -6% | -$25.2K | ﹤0.01% | 2800 |
|
|
2025
Q3 | $394K | Buy |
120,771
+489
| +0.4% | +$1.54K | ﹤0.01% | 2850 |
|
|
2025
Q2 | $295K | Buy |
120,282
+12,644
| +12% | +$64.1K | ﹤0.01% | 2999 |
|
|
2025
Q1 | $718K | Buy |
107,638
+8,299
| +8% | +$82K | ﹤0.01% | 2339 |
|
|
2024
Q4 | $1.25M | Buy |
99,339
+1,242
| +1% | +$18.7K | ﹤0.01% | 2125 |
|
|
2024
Q3 | $1.81M | Sell |
98,097
-3,037
| -3% | -$62.2K | ﹤0.01% | 1962 |
|
|
2024
Q2 | $2.18M | Buy |
101,134
+4,958
| +5% | +$114K | ﹤0.01% | 1842 |
|
|
2024
Q1 | $2.59M | Buy |
96,176
+4,163
| +5% | +$118K | ﹤0.01% | 1778 |
|
|
2023
Q4 | $2.76M | Buy |
92,013
+4,486
| +5% | +$99K | ﹤0.01% | 1748 |
|
|
2023
Q3 | $1.79M | Buy |
87,527
+3,966
| +5% | +$72.1K | ﹤0.01% | 1906 |
|
|
2023
Q2 | $1.66M | Sell |
83,561
-8,661
| -9% | -$175K | ﹤0.01% | 2009 |
|
|
2023
Q1 | $1.58M | Buy |
92,222
+7,030
| +8% | +$138K | ﹤0.01% | 1929 |
|
|
2022
Q4 | $1.67M | Buy |
85,192
+14,936
| +21% | +$275K | ﹤0.01% | 1877 |
|
|
2022
Q3 | $1.12M | Buy |
70,256
+3,961
| +6% | +$61.8K | ﹤0.01% | 2065 |
|
|
2022
Q2 | $912K | Buy |
66,295
+21,643
| +48% | +$258K | ﹤0.01% | 2187 |
|
|
2022
Q1 | $708K | Buy |
44,652
+1,575
| +4% | +$27.2K | ﹤0.01% | 2274 |
|
|
2021
Q4 | $940K | Sell |
43,077
-1,319
| -3% | -$36K | ﹤0.01% | 2240 |
|
|
2021
Q3 | $1.33M | Buy |
44,396
+1,712
| +4% | +$62.3K | ﹤0.01% | 2098 |
|
|
2021
Q2 | $1.89M | Sell |
42,684
-255
| -0.6% | -$11.1K | ﹤0.01% | 1974 |
|
|
2021
Q1 | $1.91M | Sell |
42,939
-3,001
| -7% | -$165K | ﹤0.01% | 1944 |
|
|
2020
Q4 | $2.52M | Buy |
45,940
+407
| +0.9% | +$14.8K | ﹤0.01% | 1739 |
|
|
2020
Q3 | $1.04M | Sell |
45,533
-5,950
| -12% | -$147K | ﹤0.01% | 1983 |
|
|
2020
Q2 | $1.08M | Buy |
51,483
+12,041
| +31% | +$217K | ﹤0.01% | 2012 |
|
|
2020
Q1 | $550K | Buy |
39,442
+1,949
| +5% | +$38.6K | ﹤0.01% | 2128 |
|
|
2019
Q4 | $853K | Buy |
37,493
+670
| +2% | +$11.2K | ﹤0.01% | 2151 |
|
|
2019
Q3 | $429K | Sell |
36,823
-140
| -0.4% | -$1.74K | ﹤0.01% | 2401 |
|
|
2019
Q2 | $554K | Buy |
36,963
+6,268
| +20% | +$109K | ﹤0.01% | 2321 |
|
|
2019
Q1 | $538K | Buy |
30,695
+2,573
| +9% | +$40.6K | ﹤0.01% | 2304 |
|
|
2018
Q4 | $417K | Buy |
28,122
+9,036
| +47% | +$150K | ﹤0.01% | 2384 |
|
|
2018
Q3 | $470K | Sell |
19,086
-1,201
| -6% | -$26.1K | ﹤0.01% | 2303 |
|
|
2018
Q2 | $398K | Buy |
+20,287
| New | +$384K | ﹤0.01% | 2405 |
|
|
2017
Q2 | – | Sell |
-7,456
| Closed | -$60K | – | 2948 |
|
|
2017
Q1 | $60K | Buy |
7,456
+3,000
| +67% | +$20.2K | ﹤0.01% | 2813 |
|
|
2016
Q4 | $109K | Sell |
4,456
-396
| -8% | -$11.3K | ﹤0.01% | 2785 |
|
|
2016
Q3 | $184K | Buy |
4,852
+350
| +8% | +$11K | ﹤0.01% | 2706 |
|
|
2016
Q2 | $134K | Buy |
+4,502
| New | +$158K | ﹤0.01% | 2864 |
|
Other funds holding RCKT
RI
NM
MC
RhumbLine Advisers's RCKT Position: Q2 2026 in Review
RhumbLine Advisers increased its Rocket Pharmaceuticals (RCKT) stake by 1.1% in Q2 2026, buying an estimated $4.04K and bringing the position to 111,412 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #2927.
RhumbLine Advisers first reported a position in RCKT in Q2 2016 and has held it in 37 quarters since. The position peaked at $2.76M in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.
- RhumbLine Advisers held 111,412 shares of Rocket Pharmaceuticals worth $381K as of Q2 2026.
- RhumbLine Advisers bought 1,216 Rocket Pharmaceuticals shares in Q2 2026, an estimated $4.04K.
- Rocket Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2927 holding.
- RhumbLine Advisers first reported a position in Rocket Pharmaceuticals in Q2 2016 and has held it in 37 quarters since.
- RhumbLine Advisers's Rocket Pharmaceuticals position peaked at $2.76M in Q4 2023.
- 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.